CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic

Checkpoint blocking antibodies targeting regulatory molecules on T cells such as CTLA-4 and PD-1 have reinvigorated the field of cancer immunotherapy. These agents have demonstrated clinical activity across a variety of tumor types. Now that safety and clinical activity has been demonstrated in the...

Descripción completa

Detalles Bibliográficos
Autores principales: Callahan, Margaret K., Postow, Michael A., Wolchok, Jedd D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2015
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4295550/
https://www.ncbi.nlm.nih.gov/pubmed/25642417
http://dx.doi.org/10.3389/fonc.2014.00385
Descripción
Sumario:Checkpoint blocking antibodies targeting regulatory molecules on T cells such as CTLA-4 and PD-1 have reinvigorated the field of cancer immunotherapy. These agents have demonstrated clinical activity across a variety of tumor types. Now that safety and clinical activity has been demonstrated in the monotherapy setting, the field is moving in the direction of testing novel combinations.

Ejemplares similares